Voyager Therapeutics, Inc.VYGRNASDAQ

Revenue (LTM)

$40M

-49.5% YoY

Net Income (LTM)

$-120M

-84.2% YoY

Free Cash Flow

$-135M

Revenue CAGR (5Y)

+1.9%

Marginsimproving

FCF($0.1B)

Unprofitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	37	41↑9.3%	250↑511.2%	80↓68.0%	40↓49.5%
Gross Profit	-36	-15↑59.2%	158↑1162.4%	80↓49.3%	36↓54.6%
Operating Income	-74	-51↑30.9%	122↑340.0%	-83↓168.3%	-132↓58.3%
Net Income	-71	-46↑34.8%	132↑385.1%	-65↓149.1%	-120↓84.2%
EBITDA	-68	-40↑42.1%	126↑419.0%	-79↓162.1%	-128↓62.7%
EPS Diluted	-1.75	-1.21↑30.9%	2.97↑345.5%	-1.13↓138.0%	-2.04↓80.5%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	117	99↓15.7%	69↓30.5%	71↑3.7%	65↓8.5%
Total Current Assets	137	124↓8.9%	320↑156.8%	277↓13.4%	203↓26.8%
Total Assets	194	159↓17.8%	351↑120.4%	393↑11.9%	252↓35.8%
Total Current Liabilities	51	73↑42.4%	65↓11.1%	50↓22.8%	27↓46.7%
Total Liabilities	99	100↑1.6%	115↑14.6%	93↓18.9%	56↓39.8%
Total Equity	95	59↓37.9%	236↑300.4%	300↑26.8%	196↓34.6%
Total Debt	44	23↓47.7%	20↓12.2%	44↑115.5%	36↓16.5%
Net Debt	-73	-76↓3.5%	-49↑36.0%	-28↑43.0%	-29↓4.2%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	-54	-13↑76.6%	78↑722.9%	-15↓119.6%	-132↓765.2%
Capital Expenditure	-2	-2↓54.8%	-3↓30.7%	-4↓8.1%	-3↑26.3%
Free Cash Flow	-55	-15↑72.8%	75↑597.8%	-19↓125.2%	-135↓617.2%
Stock-Based Comp	11	9↓17.5%	11↑19.4%	15↑32.6%	15↑0.0%
Net Change in Cash	13	-18↓242.2%	-30↓62.8%	4↑112.8%	-6↓261.3%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance